Vycline Tablets (Famciclovir)

Adult dose

1. Treatment of herpes zoster Adults: Administer 250 mg of famciclovir per dose orally 3 times daily for 7 days. It is preferable to start treatment as soon as symptoms appear after infection. 2. Treatment of first-episode genital herpes Adults: Administer 250 mg of this medicine per dose orally 3 times daily for 5 days. It is preferable to start treatment as soon as symptoms appear after infection. 3. Treatment of acute recurrent genital herpes Adults: Administer 125 mg of this medicine per dose orally twice daily for 5 days. It is preferable to start treatment during the prodromal period or as soon as symptoms appear after infection. 4. Suppression of recurrent genital herpes Adults: Administer 250 mg of this medicine per dose orally twice daily. Discontinue treatment periodically every 6～12 months to assess whether the natural course of the disease has changed. 5. Patients with renal impairment: Since creatinine clearance of this medicine is reduced in patients with renal impairment, dose adjustment should be undertaken with care. The dosage and administration for these patients are as follows. 1) Treatment of herpes zoster and first-episode genital herpes: Creatinine clearance (mL/min/1.73㎡) 30～59: 250 mg per dose twice daily 10～29: 250 mg per dose once daily 2) Treatment of acute recurrent genital herpes: Creatinine clearance (mL/min/1.73㎡) 30～59: 125 mg per dose twice daily 10～29: 125 mg per dose once daily 3) Suppression of recurrent genital herpes: Creatinine clearance (mL/min/1.73㎡) 30～59: 250 mg per dose twice daily 10～29: 125 mg per dose twice daily 4) If only serum creatinine is known, creatinine clearance may be calculated using the following formulas. Men: {body weight (kg) × (140-age)}/ {72 × serum creatinine (mg/dL)} Women: 0.85 × the value calculated for men 5) Patients with renal impairment undergoing hemodialysis For patients on hemodialysis, administration every 48 hours, taking the dialysis interval into account, is preferable. Since 4 hours of hemodialysis reduces the plasma concentration of this medicine by approximately 75%, administer this medicine immediately after dialysis. The recommended dose is 250mg for patients with herpes zoster and 125mg for patients with genital herpes. 6. Patients with hepatic impairment: No dose adjustment is required in patients with compensated chronic liver disease. There is insufficient treatment experience in patients with overt chronic decompensated liver disease; therefore, a clear recommended dose has not been established.

This medication should not be used in patients with a known allergy to this drug or its components, or to its main active ingredient, penciclovir. Patients with impaired kidney function should be especially cautious when using this medication, and dosage adjustments may be necessary. Mild side effects such as headache or nausea may occur during the course of this medication; however, most are not severe and are temporary. Rarely, there may be a decrease in platelet count or reductions in white blood cells and neutrophils, so blood tests may be required. Central nervous system symptoms such as dizziness, drowsiness, and confusion may occur, so it is advisable to avoid driving or operating machinery if these symptoms present. Gastrointestinal symptoms such as nausea, vomiting, abdominal pain, and diarrhea may commonly occur. Liver dysfunction or skin rashes, itching may arise, and if these abnormal symptoms persist, it is essential to inform a doctor. In patients with reduced kidney function, acute renal failure may occur rarely; therefore, kidney function should be monitored periodically. This medication does not fully cure genital herpes, so there remains a risk of transmission during sexual contact even while undergoing treatment; therefore, safe sexual practices should be maintained. Women who are pregnant or may become pregnant should carefully consider using this medication after thorough consultation with a doctor. Breastfeeding women are also advised to consult with a doctor considering the likelihood of this medication passing into breast milk. The safety and efficacy of this medication have not been established in children under 18 years of age, so its use is not recommended. Elderly patients generally do not require dosage adjustments; however, dosage should be adjusted if kidney function is impaired. In case of an overdose of this medication, immediate medical attention should be sought for appropriate treatment, and dialysis may be helpful. This medication should be stored in a sealed container to protect it from air and moisture. It should be stored in a cool and dry place at temperatures below 30 degrees Celsius, and kept out of the reach of children. Transferring the medication to other containers may lead to misuse or deterioration of quality, so this should be avoided.

• headache
• nausea
• thrombocytopenia
• leukopenia
• neutropenia
• dizziness
• confusion
• drowsiness
• hallucination
• palpitations

This medication should be stored in a sealed container to protect it from air and moisture. Additionally, it should be kept in a cool and dry place at temperatures below 30 degrees Celsius to maintain its efficacy.

Appearance

White round film-coated tablets

Package unit

21 tablets/PTP